Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1751 to 1760 of 2603 total matches.
Breathe Right Nasal Strips to Decrease Snoring
The Medical Letter on Drugs and Therapeutics • Oct 28, 1994 (Issue 934)
nasal dilators (CNS, Chanhassen, MN) are adhesive
strips 2 or 2 ⁄
1
2 inches long with a plastic ...
Breathe Right, an adhesive bandage device that pulls open the nostrils, has been approved by the US Food and Drug Administration and is being heavily promoted to the general public as a treatment for snoring and night-time nasal congestion. The manufacturer's suggested retail price is $4.99 for a box of 10 strips.
Peginterferon Alfa-2b (Sylatron) for Melanoma
The Medical Letter on Drugs and Therapeutics • Sep 19, 2011 (Issue 1373)
different between the two groups.1
ADVERSE EFFECTS — During the clinical trial, the
most common adverse ...
The FDA has approved peginterferon alfa-2b (Sylatron – Merck) for adjuvant treatment of node-positive melanoma after surgical resection. Pegylated interferon has a longer duration of action than interferon alfa-2b (Intron A), which is also FDA-approved for adjuvant treatment of malignant melanoma after surgery, and can be given once a week, compared to 3-5 times a week for standard interferon.
Off-Label Use of Ketorolac for Athletic Injuries
The Medical Letter on Drugs and Therapeutics • May 14, 2012 (Issue 1390)
muscles, has become a common
practice in US locker rooms.1
KETOROLAC — A non-selective NSAID available ...
Recent reports indicate that intramuscular (IM) injection
of the nonsteroidal anti-inflammatory drug
(NSAID) ketorolac (Toradol, and others), sometimes
directly into injured muscles, has become a common
practice in US locker rooms.
In Brief: Meningococcal Vaccine for Infants
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013 (Issue 1429)
, antibody levels against Hib were non-inferior
to those with 2 standard monovalent Hib vaccines.1 ...
Rates of meningococcal disease are highest in infancy, but until recently no meningococcal vaccine was approved for use in this age group. MenHibrix (GSK), a new conjugate vaccine that protects against Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib), has been approved by the FDA for use in infants ≥6 weeks old and Menveo, a meningococcal vaccine already approved for patients ≥2 years old that protects against serogroups A, C, Y, and W-135, is now approved for use in infants ≥2 months old.SEROGROUPS — Five major serogroups of N. meningitidis, A, B, C,...
Sorafenib (Nexavar) for Thyroid Cancer
The Medical Letter on Drugs and Therapeutics • May 26, 2014 (Issue 1443)
cell and unresectable hepatocellular cancer.1
STANDARD TREATMENT — Surgery and radioactive
iodine ...
The FDA has approved the use of the oral multikinase
inhibitor sorafenib (Nexavar – Bayer) for treatment
of locally recurrent or metastatic, progressive,
differentiated thyroid cancer (papillary or follicular)
refractory to radioactive iodine treatment. Sorafenib
was approved earlier for treatment of advanced renal
cell and unresectable hepatocellular cancer.
In Brief: New Indications for Secukinumab (Cosentyx)
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016 (Issue 1496)
and ankylosing spondylitis
in adults.1 Secukinumab is one of the most effective drugs
available for treatment ...
The FDA has approved the subcutaneous IL-17A antagonist secukinumab (Cosentyx - Novartis), which was first approved in 2015 for treatment of plaque psoriasis, for treatment of psoriatic arthritis and ankylosing spondylitis in adults.1 Secukinumab is one of the most effective drugs available for treatment of plaque psoriasis.2FDA approval of secukinumab for treatment of psoriatic arthritis was based on two randomized, double-blind trials with a primary endpoint of at least a 20% improvement in the American College of Rheumatology response criteria (ACR20) at 24 weeks. In both trials, ACR20...
In Brief: Erenumab (Aimovig) Hypersensitivity
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
of erenumabaooe
(Aimovig)1, a once-monthly, subcutaneously injected
calcitonin gene-related peptide (CGRP ...
The FDA has approved changes to the labeling of erenumab-aooe (Aimovig)1, a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) blocker approved in 2018 for prevention of migraine. The new label contains a warning about hypersensitivity reactions, including rash, angioedema, and anaphylaxis, that have been reported with post-marketing use of the drug.According to the label, most of these reactions were not serious and occurred within hours after receiving the drug, but some occurred more than one week after administration. Because these reactions are voluntarily...
Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
tonic-clonic” (see Table 1). The new terminology is used here.
Controlled monotherapy trials ...
When used for the appropriate seizure type,
antiseizure medications (ASMs) are roughly
equivalent in efficacy. In addition to the seizure type,
the choice of drug is usually based on factors such
as ease of use, spectrum of activity, adverse effects,
interactions with other drugs, presence of comorbid
conditions, suitability for elderly persons and those
with childbearing potential, and cost. Treatment
should begin with a single drug, increasing the
dosage gradually until seizures are controlled or
adverse effects become unacceptable. If seizures
persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8 doi:10.58347/tml.2024.1708a | Show Introduction Hide Introduction
Drugs for Assisted Reproduction
Treatment Guidelines from The Medical Letter • Oct 01, 2003 (Issue 14)
. (ISSN 1541-2784)
Vol. 1 (Issue 14) October 2003
Published by The Medical Letter, Inc.
1000 Main ...
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
In Brief: A Naloxone Auto-Injector (Evzio)
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
from opioid overdose in the US.1 Now the FDA has
approved a more practical alternative for emergency ...
A recent Medical Letter article reported renewed interest in the intranasal administration (off-label) of the opioid antagonist naloxone because of an increase in deaths from opioid overdose in the US.1 Now the FDA has approved a more practical alternative for emergency treatment of life-threatening opioid overdose in adults and children: a single-dose naloxone auto-injector (Evzio – Kaleo) for intramuscular or subcutaneous use.Evzio will be available in kits containing two prefilled 0.4-mg auto-injectors with voice guidance and a "trainer" device that also has voice guidance, but does not...